Difference between revisions of "Aldesleukin (Proleukin)"
m (Text replacement - "http://chemocare.com/chemotherapy" to "https://chemocare.com/chemotherapy") |
m |
||
| Line 5: | Line 5: | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://reference.medscape.com/drug/interleukin-2-proleukin-aldesleukin-342203 Medscape], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://reference.medscape.com/drug/interleukin-2-proleukin-aldesleukin-342203 Medscape], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| + | |||
| + | ==Diseases for which it is established== | ||
| + | *[[Renal cell carcinoma]] | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Melanoma]] | *[[Melanoma]] | ||
*[[Neuroblastoma]] | *[[Neuroblastoma]] | ||
| − | |||
==Patient drug information== | ==Patient drug information== | ||
Revision as of 00:17, 20 May 2022
General information
Class/mechanism: Recombinant interleukin-2 which activates the immune system. Aldesleukin encourages growth of IL-2 dependent cells, triggers natural killer (NK) and lymphokine-activated killer (LAK) cell activity, induces production of interferon gamma, and increases lymphocyte cytotoxicity.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is established
Diseases for which it is used
Patient drug information
- Aldesleukin (Proleukin) patient drug information (Chemocare)[4]
- Aldesleukin (Proleukin) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 5/5/1992: Initial approval for treatment of adults (>18 years old) with metastatic renal cell carcinoma
Also known as
- Generic names: Interleukin-2, IL-2
- Brand names: Macrolin, Proleukin